You just read:

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors

News provided by

Cyteir Therapeutics

Mar 31, 2019, 13:00 ET